Literature DB >> 15872296

Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy.

B Zöllner1, M Sterneck, K Wursthorn, J Petersen, M Schröter, R Laufs, H-H Feucht.   

Abstract

The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naive patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15872296      PMCID： PMC1153772          DOI： 10.1128/JCM.43.5.2503-2505.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Viral features of lamivudine resistant hepatitis B genotypes A and D.

Authors:  Bernhard Zöllner; Jörg Petersen; Elisabeth Puchhammer-Stöckl; Josef Kletzmayr; Martina Sterneck; Lutz Fischer; Matthias Schröter; Rainer Laufs; Heinz-Hubert Feucht
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

2.  Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein.

Authors:  Shiow-Yi Chen; Chih-Fei Kao; Chun-Ming Chen; Chwen-Ming Shih; Ming-Jen Hsu; Chi-Hong Chao; Shao-Hung Wang; Li-Ru You; Yan-Hwa Wu Lee
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

3.  In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.

Authors:  X Xiong; H Yang; C E Westland; R Zou; C S Gibbs
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

4.  Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis.

Authors:  E Sagnelli; N Coppola; C Scolastico; P Filippini; T Santantonio; T Stroffolini; F Piccinino
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

5.  Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers.

Authors:  S Kobayashi; T Ide; M Sata
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

6.  Lamivudine as initial treatment for chronic hepatitis B in the United States.

Authors:  J L Dienstag; E R Schiff; T L Wright; R P Perrillo; H W Hann; Z Goodman; L Crowther; L D Condreay; M Woessner; M Rubin; N A Brown
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

7.  High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system.

Authors:  K R Loeb; K R Jerome; J Goddard; M Huang; A Cent; L Corey
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

8.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Authors:  M I Allen; M Deslauriers; C W Andrews; G A Tipples; K A Walters; D L Tyrrell; N Brown; L D Condreay
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

9.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.

Authors:  L Fu; Y C Cheng
Journal:  Biochem Pharmacol       Date:  1998-05-15       Impact factor: 5.858

10.  Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.

Authors:  Pilar León; Francisco Pozo; José M Echevarría
Journal:  Enferm Infecc Microbiol Clin       Date:  2004-03       Impact factor: 1.731
View more
  10 in total

1.  HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.

Authors:  H N Kim; J Scott; A Cent; L Cook; R A Morrow; B Richardson; K Tapia; K R Jerome; G Lule; G John-Stewart; M H Chung
Journal:  J Viral Hepat       Date:  2011-05-13       Impact factor: 3.728

2.  The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

Authors:  Nadia Warner; Stephen Locarnini; Michael Kuiper; Angeline Bartholomeusz; Anna Ayres; Lilly Yuen; Tim Shaw
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

3.  Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.

Authors:  Verena Schildgen; Susanne Ziegler; Ramona L Tillmann; Oliver Schildgen
Journal:  Virol J       Date:  2010-07-21       Impact factor: 4.099

4.  Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B.

Authors:  Jie Xu; Biao Wu; Jing-Hui Wang; Ling Huang; Deng-Yu Wang; Ling Zhao; Guo-Ping Zhao; Ying Wang
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

5.  HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining.

Authors:  Xizhan Xu; Kuanhui Xiang; Mingze Su; Yao Li; Wei Ji; Yutang Li; Hui Zhuang; Tong Li
Journal:  Viruses       Date:  2017-07-27       Impact factor: 5.048

6.  Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.

Authors:  Xiaoman Zhang; Xianli Chen; Meijuan Wei; Chunyu Zhang; Tao Xu; Liguan Liu; Zhengju Xu
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

7.  Association of Pre-S/S and Polymerase Mutations with Acute and Chronic Hepatitis B Virus Infections in Patients from Rio de Janeiro, Brazil.

Authors:  Camilla Rodrigues de Almeida Ribeiro; Katrini Guidolini Martinelli; Vinícius da Motta de Mello; Natália Spitz; Oscar Rafael Carmo Araújo; Lia Laura Lewis-Ximenez; Natalia Motta Araujo; Vanessa Salete de Paula
Journal:  Viruses       Date:  2022-06-24       Impact factor: 5.818

8.  Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes.

Authors:  Son V Chu; Son T Vu; Hang M Nguyen; Ngan T Le; Phuong T Truong; Van T T Vu; Thuy T B Phung; Anh T V Nguyen
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

Review 9.  Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.

Authors:  Yu-Min Choi; So-Young Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

10.  Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.

Authors:  Ronald E Rose; Dennis Hernandez; Paul J Falk; Karen Ericson; Nannan Zhou; Alexandra Thiry; Fiona McPhee
Journal:  Hepatol Commun       Date:  2018-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.